

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in this application:

Listing of Claims

1. (Canceled)
2. (Canceled)
3. (Previously Presented) The compound according to claim 153 consisting of from 12-40 nucleotides.
4. (Canceled)
5. (Previously Presented) The compound according to claim 3 consisting of from 12-20 nucleotides.
6. (Original) The compound according to claim 5 consisting of 12, 13, 14, 15, 16, 17, 18, 19 or 20 nucleotides.
7. (Original) The compound according to claim 6 consisting of 14, 15, 16, 17 or 18 nucleotides.
8. (Original) The compound according to claim 5 consisting of from 15-17 nucleotides.
9. (Original) The compound according to claim 8 consisting of 15, 16 or 17 nucleotides.
10. (Original) The compound according to claim 8 consisting of 15 nucleotides.

11. (Original) The compound according to claim 9 consisting of 16 nucleotides.
12. (Original) The compound according to claim 9 consisting of 17 nucleotides.
13. (Previously Presented) The compound according claim 153, comprising a subsequence of at least 10 nucleotides or nucleotide analogues.
14. (Previously Presented) The compound according to claim 153, comprising a subsequence of at least 12 nucleotides or nucleotide analogues.
15. (Previously Presented) The compound according to claim 153, comprising a subsequence of at least 14 nucleotides or nucleotide analogues.
16. (Previously Presented) The compound according to claim 153, comprising a subsequence of 10, 11, 12, 13 14, 15 or 16 nucleotides or nucleotide analogues.
17. (Cancel)
18. (Cancel)
19. (Previously Presented) The compound according to claim 160, wherein said linkage is a phosphate group.
20. (Previously Presented) The compound according to claim 160, wherein said linkage is phosphorothioate group.
21. (Previously Presented) The compound according to claim 160, wherein all nucleotides comprise a phosphorothioate group.

22. (Cancel)

23. (Previously Presented) The compound according to claim 153 comprising of from 1-50 nucleotide analogues.

24. (Original) The compound according to claim 23 comprising of from 2-45 nucleotide analogues.

25. (Original) The compound according to claim 24 comprising of from 3-40 nucleotide analogues.

26. (Original) The compound according to claim 25 comprising of from 4-35 nucleotide analogues.

27. (Original) The compound according to claim 26 comprising of from 5-30 nucleotide analogues.

28. (Original) The compound according to claim 27 comprising of from 6-25 nucleotide analogues.

29. (Original) The compound according to claim 28 comprising of from 6-20 nucleotide analogues.

30. (Original) The compound according to claim 29 comprising of from 6-12 nucleotide analogues.

31. (Original) The compound according to claim 30 comprising of from 8-12 nucleotide analogues.

32. (Original) The compound according to claim 30 comprising 6, 7, 8, 9, 10, 11 or 12 nucleotide analogues.

33. (Original) The compound according to claim 31 comprising of from 6-10 nucleotide analogues.

34. (Original) The compound according to claim 33 comprising 6, 7, 8, 9 or 10 nucleotide analogues.

35. (Original) The compound according to claim 34 comprising 7, 8 or 9 nucleotide analogues.

36. (Original) The compound according to claim 35 comprising 8 nucleotide analogues.

37. (Previously Presented) The compound according to any of claims 23-36, wherein all nucleotides are replaced by the corresponding nucleotide analogues.

38. (Previously Presented) The compound according to any of claims 23-36 comprising a nucleoside located at the 3' end.

39.-44 (Cancel)

45. (Previously Presented) The compound according to claim 153, wherein said nucleotides and/or nucleotide analogues are linked to each other by means of a phosphate group.

46. (Previously Presented) The compound according to claim 153, wherein said nucleotides and/or nucleotide analogues are linked to each other by means of a phosphorothioate group.

47. (Cancel)

48. (Previously Presented) The compound according claim 153, wherein said subsequence comprises a stretch of 2-6 LNAs followed by a stretch of 4-12 nucleotides, which is followed by a stretch of 2-6 LNAs.

49. (Previously Presented) The compound according to claim 48, wherein said subsequence comprises a stretch of 4 LNAs followed by a stretch of 8 nucleotides, which is followed by a stretch of 4 LNAs.

50. (Previously Presented) The compound according to claim 153, wherein said subsequence comprises a stretch of 2-6 LNAs followed by a stretch of 4-12 nucleotides, which is followed by a stretch of 2-5 LNAs, which is followed by a single nucleotide.

51. (Previously Presented) The compound according to claim 50, wherein said subsequence comprises a stretch of 4 LNAs followed by a stretch of 8 nucleotides, which is followed by a stretch of 3 LNAs as defined, which is followed by a single nucleotide.

52. (Previously Presented) The compound according to claim 51, wherein said single nucleoside is located at the 3' end.

53. – 119 (Cancel)

120. (Previously Presented) A conjugate comprising the compound according to claim 153 and at least one non-nucleotide or non-polynucleotide moiety covalently attached to said compound.

121. (Previously Presented) A pharmaceutical composition comprising a compound as defined in claim 153 or a conjugate as defined in claim 120, and a pharmaceutically acceptable diluent, carrier or adjuvant.

122. (Previously Presented) The pharmaceutical composition according to claim 121 further comprising at least one chemotherapeutic agent.

123. (Previously Presented) The pharmaceutical composition according to claim 122, wherein said chemotherapeutic compound is selected from the group consisting of adrenocorticosteroids, such as prednisone, dexamethasone or decadron; altretamine (hexalen, hexamethylmelamine (HMM)); amifostine (ethyol); aminoglutethimide (cytadren); amsacrine (M-AMSA); anastrozole (arimidex); androgens, such as testosterone; asparaginase (elspar); bacillus calmette-gurin; bicalutamide (casodex); bleomycin (blenoxane); busulfan (myleran); carboplatin (paraplatin); carmustine (BCNU, BiCNU); chlorambucil (leukeran); chlorodeoxyadenosine (2-CDA, cladribine, leustatin); cisplatin (platinol); cytosine arabinoside (cytarabine); dacarbazine (DTIC); dactinomycin (actinomycin-D, cosmegen); daunorubicin (cerubidine); docetaxel (taxotere); doxorubicin (adriamycin); epirubicin; estramustine (emcyt); estrogens, such as diethylstilbestrol (DES); etoposide (VP-16, VePesid, etopophos); fludarabine (fludara); flutamide (eulexin); 5-FUDR (floxuridine); 5-fluorouracil (5-FU); gemcitabine (gemzar); goserelin (zodalex); herceptin (trastuzumab); hydroxyurea (hydrea); idarubicin (idamycin); ifosfamide; IL-2 (proleukin, aldesleukin); interferon alpha (intron A, roferon A); irinotecan (camptosar); leuprolide (lupron); levamisole (ergamisole); lomustine (CCNU); mechlorathamine (mustargen, nitrogen mustard); melphalan (alkeran); mercaptopurine (purinethol, 6-MP); methotrexate (mexate); mitomycin-C (mutamucin); mitoxantrone (novantrone); octreotide (sandostatin); pentostatin (2-deoxycoformycin, nipent); plicamycin (mithramycin, mithracin); prorocarbazine (matulane); streptozocin; tamoxifen (nolvadex); taxol (paclitaxel); teniposide (vumon, VM-26); thiotepa;

topotecan (hycamtin); tretinoin (vesanoid, all-trans retinoic acid); vinblastine (valban); vincristine (oncovin) and vinorelbine (navelbine).

124. (Previously Presented) A compound as defined in claim 153 or a conjugate as defined in claim 120 for use as a medicament.

125-152 (Cancel)

153. (Currently Amended) A compound consisting of 12-50 nucleotides and/or nucleotide analogues, wherein said compound comprises a subsequence of at least 8 nucleotides or nucleotide analogues, said subsequence being located within the sequence ctcaatccatggcagc (SEQ ID NO: 130) and wherein at least one of said nucleotides in said sequence has been replaced by a corresponding nucleotide analogue.

154. (Previously Presented) The compound of claim 153, wherein said corresponding nucleotide is selected from the group consisting of LNA sugar, 2'-O-methyl DNA sugar, 2'-fluoro DNA sugar, 2'-MOE DNA sugar, 2'-O-(3-amino)propyl and 2'-O-(3-hydroxy)propyl.

155. (Previously Presented) The compound of claim 154, wherein said corresponding nucleotide is LNA.

156. (Previously Presented) The compound of claim 155, wherein said LNA is selected from the group consisting of thio-LNA, amino-LNA and oxy-LNA.

157. (Previously Presented) The compound of claim 156, wherein said LNA is beta-D-oxy-LNA.

158. (Previously Presented) The compound of claim 153, wherein said compound comprises a subsequence of at least 12 nucleotides or nucleotide analogous.

159. (Previously Presented) The compound of claim 153, wherein said compound consists of 12-20 nucleotides and/or nucleotide analogues.

160. (Currently Amended) The compound of claim 153, wherein said compound comprises the sequence CTCAatccatggCAGC (SEQ ID NO: 130) or CTCAatccatggCAGc (SEQ ID NO: 130), wherein uppercase letters denote a beta-D-oxy-LNA and lowercase letters denote a DNA sugar, and wherein said nucleotides and/or nucleotide analogues are linked together by a phosphate group, a phosphorothioate group, or a combination thereof.

161. (Currently Amended) The compound of claim 160, wherein said compound comprises the sequence C_ST_SC_SA_sast_sc_sc_sast_sgsg_sC_SA_SG_SC (SEQ ID NO:664), wherein uppercase letters denote a beta-D-oxy-LNA and lowercase letters denote a DNA sugar, and wherein the subscript "s" denotes a phosphorothioate linkage.

162. (Currently Amended) The compound of claim 161, wherein said compound consists of the sequence C_ST_SC_SA_sast_sc_sc_sast_sgsg_sC_SA_SG_SC (SEQ ID NO:664), wherein uppercase letters denote a beta-D-oxy-LNA and lowercase letters denote a DNA sugar, and wherein the subscript "s" denotes a phosphorothioate linkage.

163. (Currently Amended) The compound of claim 160, wherein said compound comprises the sequence C_OT_OC_OA_oast_sc_sc_sast_sgsg_sC_OA_OG_OC(SEQ ID NO:662), wherein uppercase letters denote a beta-D-oxy-LNA and lowercase letters denote a DNA sugar, and wherein the subscript "s" denotes a phosphorothioate linkage and the subscript "o" denotes a phosphate linkage.

164. (Currently Amended) The compound of claim 163, wherein said compound consists of the sequence C₀T₀C₀A₀a₀s₀t₀c₀s₀a₀s₀t₀g₀s₀g₀s₀C₀A₀G₀C (SEQ ID NO:662), wherein uppercase letters denote a beta-D-oxy-LNA and lowercase letters denote a DNA sugar, and wherein the subscript "s" denotes a phosphorothioate linkage and the subscript "o" denotes a phosphate linkage.

165. (Currently Amended) The compound of claim 160, wherein said compound comprises the sequence C₅T₅C₅A₅a₅s₅t₅c₅s₅a₅s₅t₅g₅s₅g₅s₅C₅A₅G₅C (SEQ ID NO:661), wherein uppercase letters denote a beta-D-oxy-LNA and lowercase letters denote a DNA sugar, and wherein the subscript "s" denotes a phosphorothioate linkage.

166. (Currently Amended) The compound of claim 165, wherein said compound consists of the sequence C₅T₅C₅A₅a₅s₅t₅c₅s₅a₅s₅t₅g₅s₅g₅s₅C₅A₅G₅C (SEQ ID NO:661), wherein uppercase letters denote a beta-D-oxy-LNA and lowercase letters denote a DNA sugar, and wherein the subscript "s" denotes a phosphorothioate linkage.

167. (Currently Amended) The compound of claim 153, wherein said compound comprises the sequence c₅t₅c₅a₅a₅s₅t₅c₅s₅a₅s₅t₅g₅s₅g₅s₅c₅a₅g₅c (SEQ ID NO:663), wherein lowercase letters denote a DNA sugar, and wherein the subscript "s" denotes a phosphorothioate linkage.

168. (Currently Amended) The compound of claim 167, wherein said compound consists of the sequence c₅t₅c₅a₅a₅s₅t₅c₅s₅a₅s₅t₅g₅s₅g₅s₅c₅a₅g₅c (SEQ ID NO:663), wherein lowercase letters denote a DNA sugar, and wherein the subscript "s" denotes a phosphorothioate linkage.

169. (Previously Presented) The compound of any one of claims 160-168, wherein the cytosine (C) is 5' methyl cytosine (5'-MeC).